Dalton Transactions · 2015 · 26 citations · 29 references
PharmacyMedicinal ChemistryOncologyCancer PharmacologyChemotherapyProdrug DesignAnticancer Prodrug DesignTumor-activated ProdrugsChemotherapeutic Prodrug DesignCytotoxicity AssaysMacromolecule SynthesisOxaliplatin-based TherapyPlatinum CompoundsPlatinum-based AgentsTargeted Chemotherapy Prodrugs
Platinum(IV)-based anticancer prodrugs have attracted much attention due to their relative inertness under physiological conditions, being activated inside cells, and their capacity for functionalization with a variety of small-molecule or macromolecule moieties. Novel asymmetric platinum(IV) compounds synthesized through expedient and unique methods are desired. Here we utilize N-bromosuccinimide (NBS) and carry out oxidative bromination on platinum(II) drugs, namely cisplatin, carboplatin, and oxaliplatin, to obtain asymmetric and mono-bromo platinum(IV) prodrugs. Different solvents are used to obtain various compounds, and the compounds are further functionalized. Di-bromo compounds are also obtained through NBS-directed oxidative bromination in ethanol. The crystal structures of representative compounds are discussed, and the reduction potentials of some compounds are examined. A cytotoxicity test shows that the mono- and di-bromo platinum(IV) compounds are active against human ovarian cancer cells. Our study enriches the family of asymmetric platinum(IV) prodrugs and provides with a convenient strategy to obtain brominated platinum(IV) complexes.
29
Platinum Compounds: a New Class of Potent Antitumour Agents
Barnett Rosenberg, Loretta Vancamp, James E. Trosko et al. · Nature · 1969 · 3.9K citations
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial Wheate, Shonagh Walker, Gemma E. Craig et al. · Dalton Transactions · 2010 · 1.6K citations
Medicine, Oncology, Pharmacology +15